메뉴 건너뛰기




Volumn 26, Issue 5, 2012, Pages

Diffuse large B-cell lymphoma: Current treatment approaches

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

EID: 84874584784     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (25)

References (57)
  • 1
    • 78649391451 scopus 로고    scopus 로고
    • Improving outcomes for patients with diffuse large B-cell lymphoma
    • Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393-408.
    • (2010) CA Cancer J Clin. , vol.60 , pp. 393-408
    • Flowers, C.R.1    Sinha, R.2    Vose, J.M.3
  • 2
    • 33745982067 scopus 로고    scopus 로고
    • Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    • Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-7.
    • (2006) J Clin Oncol. , vol.24 , pp. 3121-3127
    • Habermann, T.M.1    Weller, E.A.2    Morrison, V.A.3
  • 3
    • 38549147027 scopus 로고    scopus 로고
    • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
    • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16.
    • (2008) Lancet Oncol. , vol.9 , pp. 105-116
    • Pfreundschuh, M.1    Schubert, J.2    Ziepert, M.3
  • 4
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
    • (2002) N Engl J Med. , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 5
    • 0027444652 scopus 로고
    • The International Non-Hodgkins Lymphoma Prognostic Factors Project
    • A predictive model for aggressive non-Hodgkins lymphoma
    • A predictive model for aggressive non-Hodgkins lymphoma. The International Non-Hodgkins Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
    • (1993) N Engl J Med. , vol.329 , pp. 987-994
  • 6
    • 33847361987 scopus 로고    scopus 로고
    • The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    • Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.
    • (2007) Blood , vol.109 , pp. 1857-1861
    • Sehn, L.H.1    Berry, B.2    Chhanabhai, M.3
  • 7
    • 77952477025 scopus 로고    scopus 로고
    • Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
    • Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-80.
    • (2010) J Clin Oncol. , vol.28 , pp. 2373-2380
    • Ziepert, M.1    Hasenclever, D.2    Kuhnt, E.3
  • 8
    • 0022602852 scopus 로고
    • Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
    • Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
    • (1986) J Clin Oncol. , vol.4 , pp. 295-305
    • Dixon, D.O.1    Neilan, B.2    Jones, S.E.3
  • 9
    • 0345131723 scopus 로고    scopus 로고
    • Elderly patients with aggressive non-Hodgkins lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
    • Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkins lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352-8.
    • (1998) J Clin Oncol. , vol.16 , pp. 2352-2358
    • Gomez, H.1    Mas, L.2    Casanova, L.3
  • 10
    • 0024270189 scopus 로고
    • The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkins lymphoma
    • Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkins lymphoma. J Clin Oncol. 1988;6:1838-44.
    • (1988) J Clin Oncol. , vol.6 , pp. 1838-1844
    • Vose, J.M.1    Armitage, J.O.2    Weisenburger, D.D.3
  • 11
    • 2642651379 scopus 로고    scopus 로고
    • Elderly patients with aggressive non-Hodgkins lymphoma: Disease presentation, response to treatment, and survival--a Groupe dEtude des Lymphomes de lAdulte study on 453 patients older than 69 years
    • Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkins lymphoma: disease presentation, response to treatment, and survival--a Groupe dEtude des Lymphomes de lAdulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-53.
    • (1997) J Clin Oncol. , vol.15 , pp. 2945-2953
    • Bastion, Y.1    Blay, J.Y.2    Divine, M.3
  • 12
    • 41549137352 scopus 로고    scopus 로고
    • Non-Hodgkins lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome
    • Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkins lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. 2008;19:774-9.
    • (2008) Ann Oncol. , vol.19 , pp. 774-779
    • Thieblemont, C.1    Grossoeuvre, A.2    Houot, R.3
  • 13
    • 34249293980 scopus 로고    scopus 로고
    • Racial differences in the incidence and outcomes for patients with hematological malignancies
    • Flowers CR, Glover R, Lonial S, et al. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer. 2007;31:182-201.
    • (2007) Curr Probl Cancer. , vol.31 , pp. 182-201
    • Flowers, C.R.1    Glover, R.2    Lonial, S.3
  • 14
    • 80052042959 scopus 로고    scopus 로고
    • Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States
    • Dec 22 [Epub ahead of print]
    • Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2010;Dec 22 [Epub ahead of print].
    • (2010) Cancer
    • Shenoy, P.J.1    Malik, N.2    Nooka, A.3
  • 15
    • 79251536246 scopus 로고    scopus 로고
    • Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: A matched cohort analysis
    • abstr 1392
    • Shenoy PJ, Bumpers K, King N, et al. Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: a matched cohort analysis. ASH Annual Meeting Abstracts 2009;114:abstr 1392.
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Shenoy, P.J.1    Bumpers, K.2    King, N.3
  • 16
    • 0037142053 scopus 로고    scopus 로고
    • The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    • Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-47.
    • (2002) N Engl J Med. , vol.346 , pp. 1937-1947
    • Rosenwald, A.1    Wright, G.2    Chan, W.C.3
  • 17
    • 0034598746 scopus 로고    scopus 로고
    • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    • Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11.
    • (2000) Nature , vol.403 , pp. 503-511
    • Alizadeh, A.A.1    Eisen, M.B.2    Davis, R.E.3
  • 18
    • 54049147790 scopus 로고    scopus 로고
    • Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
    • Rimsza LM, LeBlanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112:3425-33.
    • (2008) Blood , vol.112 , pp. 3425-3433
    • Rimsza, L.M.1    LeBlanc, M.L.2    Unger, J.M.3
  • 19
    • 0141672946 scopus 로고    scopus 로고
    • Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    • Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-62.
    • (2003) J Exp Med. , vol.198 , pp. 851-862
    • Rosenwald, A.1    Wright, G.2    Leroy, K.3
  • 20
    • 57149089307 scopus 로고    scopus 로고
    • Stromal gene signatures in large-B-cell lymphomas
    • Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-23.
    • (2008) N Engl J Med. , vol.359 , pp. 2313-2323
    • Lenz, G.1    Wright, G.2    Dave, S.S.3
  • 21
    • 9144237554 scopus 로고    scopus 로고
    • Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    • Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82.
    • (2004) Blood , vol.103 , pp. 275-282
    • Hans, C.P.1    Weisenburger, D.D.2    Greiner, T.C.3
  • 22
    • 68549124173 scopus 로고    scopus 로고
    • A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
    • Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494-502.
    • (2009) Clin Cancer Res. , vol.15 , pp. 5494-5502
    • Choi, W.W.1    Weisenburger, D.D.2    Greiner, T.C.3
  • 23
    • 79951990286 scopus 로고    scopus 로고
    • Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab
    • Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29:200-7.
    • (2011) J Clin Oncol. , vol.29 , pp. 200-207
    • Meyer, P.N.1    Fu, K.2    Greiner, T.C.3
  • 24
    • 70349575802 scopus 로고    scopus 로고
    • Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival
    • Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273-9.
    • (2009) Blood , vol.114 , pp. 2273-2279
    • Johnson, N.A.1    Savage, K.J.2    Ludkovski, O.3
  • 25
    • 33645791771 scopus 로고    scopus 로고
    • Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study
    • Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207-13.
    • (2006) Blood , vol.107 , pp. 4207-4213
    • Winter, J.N.1    Weller, E.A.2    Horning, S.J.3
  • 26
    • 77950967521 scopus 로고    scopus 로고
    • Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: A prospective ECOG and Southwest Oncology Group correlative study on E4494
    • Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010;16:2435-42.
    • (2010) Clin Cancer Res. , vol.16 , pp. 2435-2442
    • Winter, J.N.1    Li, S.2    Aurora, V.3
  • 27
    • 77954752069 scopus 로고    scopus 로고
    • Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
    • Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-5.
    • (2010) J Clin Oncol. , vol.28 , pp. 3360-3365
    • Barrans, S.1    Crouch, S.2    Smith, A.3
  • 29
    • 64649093421 scopus 로고    scopus 로고
    • Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkins lymphoma and diffuse large B-cell lymphoma: A systematic review
    • Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkins lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-14.
    • (2009) J Clin Oncol. , vol.27 , pp. 1906-1914
    • Terasawa, T.1    Lau, J.2    Bardet, S.3
  • 30
    • 84874626763 scopus 로고    scopus 로고
    • Prognostic value of 18F-FDG positron emission tomography used for assessment of the first line therapy in 410 diffuse large B-cell lymphoma patients: A daily practice evaluation before and after the prescription of this metabolic imaging technique
    • Ghesquieres H, Ferlay C, Lavergne E, et al. Prognostic value of 18F-FDG positron emission tomography used for assessment of the first line therapy in 410 diffuse large B-cell lymphoma patients: a daily practice evaluation before and after the prescription of this metabolic imaging technique. Blood. 2011;118:3686.
    • (2011) Blood , vol.118 , pp. 3686
    • Ghesquieres, H.1    Ferlay, C.2    Lavergne, E.3
  • 31
    • 77951638691 scopus 로고    scopus 로고
    • Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma
    • Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010; 28:1896-903.
    • (2010) J Clin Oncol. , vol.28 , pp. 1896-1903
    • Moskowitz, C.H.1    Schoder, H.2    Teruya-Feldstein, J.3
  • 32
    • 84874643185 scopus 로고    scopus 로고
    • Interim restaging PET/CT-guided high dose sequential induction therapy with autologous stem cell transplantation (ASCT) does not improve outcome for poor prognosis diffuse large B-cell lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179
    • Stewart DA, Kloiber R, Bahlis N, et al: Interim restaging PET/CT-guided high dose sequential induction therapy with autologous stem cell transplantation (ASCT) does not improve outcome for poor prognosis diffuse large B-cell lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179. Blood. 2011;118:500.
    • (2011) Blood , vol.118 , pp. 500
    • Stewart, D.A.1    Kloiber, R.2    Bahlis, N.3
  • 33
    • 77949312595 scopus 로고    scopus 로고
    • Interim positron emission tomography scans in diffuse large B-cell lymphoma: An independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
    • Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-7.
    • (2010) Blood , vol.115 , pp. 775-777
    • Horning, S.J.1    Juweid, M.E.2    Schoder, H.3
  • 34
    • 0028793717 scopus 로고
    • High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkins lymphoma: A dose-finding pilot study
    • Shipp MA, Neuberg D, Janicek M, et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkins lymphoma: a dose-finding pilot study. J Clin Oncol. 1995;13:2916-23.
    • (1995) J Clin Oncol. , vol.13 , pp. 2916-2923
    • Shipp, M.A.1    Neuberg, D.2    Janicek, M.3
  • 35
    • 0037676141 scopus 로고    scopus 로고
    • Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349)
    • Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003;21:2466-73.
    • (2003) J Clin Oncol. , vol.21 , pp. 2466-2473
    • Blayney, D.W.1    LeBlanc, M.L.2    Grogan, T.3
  • 36
    • 10744224285 scopus 로고    scopus 로고
    • Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
    • Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284-9.
    • (2003) Blood , vol.102 , pp. 4284-4289
    • Tilly, H.1    Lepage, E.2    Coiffier, B.3
  • 37
    • 3242802160 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634-41.
    • (2004) Blood , vol.104 , pp. 634-641
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3
  • 38
    • 0033890745 scopus 로고    scopus 로고
    • Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkins lymphoma: Final analysis of the prospective LNH87-2 protocol--a groupe dEtude des lymphomes de lAdulte study
    • Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkins lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe dEtude des lymphomes de lAdulte study. J Clin Oncol. 2000;18:3025-30.
    • (2000) J Clin Oncol. , vol.18 , pp. 3025-3030
    • Haioun, C.1    Lepage, E.2    Gisselbrecht, C.3
  • 39
    • 0027394689 scopus 로고
    • Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma
    • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. N Engl J Med. 1993;328:1002-6.
    • (1993) N Engl J Med. , vol.328 , pp. 1002-1006
    • Fisher, R.I.1    Gaynor, E.R.2    Dahlberg, S.3
  • 40
    • 3042813710 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
    • German High-Grade Non-Hodgkin's Lymphoma Study Group
    • Pfreundschuh M, Trümper L, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-33.
    • (2004) Blood , vol.104 , pp. 626-633
    • Pfreundschuh, M.1    Trümper, L.2    Kloess, M.3
  • 41
    • 20144369743 scopus 로고    scopus 로고
    • ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
    • Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197-205.
    • (2005) N Engl J Med. , vol.352 , pp. 1197-1205
    • Reyes, F.1    Lepage, E.2    Ganem, G.3
  • 42
    • 0032530342 scopus 로고    scopus 로고
    • Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    • Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32.
    • (1998) Blood , vol.92 , pp. 1927-1932
    • Coiffier, B.1    Haioun, C.2    Ketterer, N.3
  • 43
    • 0035863406 scopus 로고    scopus 로고
    • Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkins lymphoma
    • Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkins lymphoma. J Clin Oncol. 2001;19:389-97.
    • (2001) J Clin Oncol. , vol.19 , pp. 389-397
    • Vose, J.M.1    Link, B.K.2    Grossbard, M.L.3
  • 44
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91.
    • (2006) Lancet Oncol. , vol.7 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 45
    • 42249097618 scopus 로고    scopus 로고
    • Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients
    • abstr 8009
    • Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol. 2007;25(18S):abstr 8009.
    • (2007) J Clin Oncol. , vol.25 , Issue.18 S
    • Coiffier, B.1    Feugier, P.2    Mounier, N.3
  • 46
    • 38449114046 scopus 로고    scopus 로고
    • CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the Hellenic Cooperative Oncology Group
    • Economopoulos T, Psyrri A, Dimopoulos MA, et al. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J. 2007;13:327-34.
    • (2007) Cancer J. , vol.13 , pp. 327-334
    • Economopoulos, T.1    Psyrri, A.2    Dimopoulos, M.A.3
  • 47
    • 80054750428 scopus 로고    scopus 로고
    • R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma
    • abstr 8000
    • Cunningham D, Smith P, Mouncey W, et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29:abstr 8000.
    • (2011) J Clin Oncol. , vol.29
    • Cunningham, D.1    Smith, P.2    Mouncey, W.3
  • 48
    • 77951805009 scopus 로고    scopus 로고
    • R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: Results of the interim analysis of the LNH03-6B GELA study
    • abstr 406
    • Delarue R, Tilley H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. ASH Annual Meeting Abstracts. 2009;114(22):abstr 406.
    • (2009) ASH Annual Meeting Abstracts. , vol.114 , Issue.22
    • Delarue, R.1    Tilley, H.2    Salles, G.3
  • 49
    • 45749152667 scopus 로고    scopus 로고
    • Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    • Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717-24.
    • (2008) J Clin Oncol. , vol.26 , pp. 2717-2724
    • Wilson, W.H.1    Dunleavy, K.2    Pittaluga, S.3
  • 50
    • 84861392779 scopus 로고    scopus 로고
    • A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
    • Dec 1 [Epub ahead of print]
    • Wilson W, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2011 Dec 1 [Epub ahead of print].
    • (2011) Haematologica
    • Wilson, W.1    Jung, S.H.2    Porcu, P.3
  • 51
    • 12144286396 scopus 로고    scopus 로고
    • Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support
    • Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-95.
    • (2004) N Engl J Med. , vol.350 , pp. 1287-1295
    • Milpied, N.1    Deconinck, E.2    Gaillard, F.3
  • 52
    • 44949229297 scopus 로고    scopus 로고
    • High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults
    • Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. 2008;1:CD004024.
    • (2008) Cochrane Database Syst Rev. , vol.1
    • Greb, A.1    Bohlius, J.2    Schiefer, D.3
  • 53
    • 80052980811 scopus 로고    scopus 로고
    • Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL)
    • abstr 8001
    • Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 2011;29(suppl):abstr 8001.
    • (2011) J Clin Oncol. , vol.29 , Issue.SUPPL.
    • Stiff, P.J.1    Unger, J.M.2    Cook, J.3
  • 54
    • 77958453257 scopus 로고    scopus 로고
    • High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
    • German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    • Glass B, Ziepert M, Reiser M, et al; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2255-61.
    • (2010) Ann Oncol. , vol.21 , pp. 2255-2261
    • Glass, B.1    Ziepert, M.2    Reiser, M.3
  • 55
    • 79952982718 scopus 로고    scopus 로고
    • A decade of progress in lymphoma: Advances and continuing challenges
    • Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk. 2010;10:414-23.
    • (2010) Clin Lymphoma Myeloma Leuk. , vol.10 , pp. 414-423
    • Flowers, C.R.1    Armitage, J.O.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.